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Abstract 
Background: (−)‑α‑Bisabolol, also known as levomenol, is an unsaturated sesquiterpene alcohol that has mainly 
been used in pharmaceutical and cosmetic products due to its anti‑inflammatory and skin‑soothing properties. 
(−)‑α‑Bisabolol is currently manufactured mainly by steam‑distillation of the essential oils extracted from the Brazilian 
candeia tree that is under threat because its natural habitat is constantly shrinking. Therefore, microbial production of 
(−)‑α‑bisabolol plays a key role in the development of its sustainable production from renewable feedstock.
Results: Here, we created an Escherichia coli strain producing (−)‑α‑bisabolol at high titer and developed an in situ 
extraction method of (−)‑α‑bisabolol, using natural vegetable oils. We expressed a recently identified (−)‑α‑bisabolol 
synthase isolated from German chamomile (Matricaria recutita) (titer: 3 mg/L), converted the acetyl‑CoA to meva‑
lonate, using the biosynthetic mevalonate pathway (12.8 mg/L), and overexpressed farnesyl diphosphate synthase 
to efficiently supply the (−)‑α‑bisabolol precursor farnesyl diphosphate. Combinatorial expression of the exogenous 
mevalonate pathway and farnesyl diphosphate synthase enabled a dramatic increase in (−)‑α‑bisabolol production in 
the shake flask culture (80 mg/L) and 5 L bioreactor culture (342 mg/L) of engineered E. coli harboring (−)‑α‑bisabolol 
synthase. Fed‑batch fermentation using a 50 L fermenter was conducted after optimizing culture conditions, resulting 
in efficient (−)‑α‑bisabolol production with a titer of 9.1 g/L. Moreover, a green, downstream extraction process using 
vegetable oils was developed for in situ extraction of (−)‑α‑bisabolol during fermentation and showed high yield 
recovery (>98%).
Conclusions: The engineered E. coli strains and economically viable extraction process developed in this study will 
serve as promising platforms for further development of microbial production of (−)‑α‑bisabolol at large scale.
Keywords: (−)‑α‑Bisabolol, (−)‑α‑Bisabolol synthase, Mevalonate pathway, Farnesyl diphosphate synthase, In situ 
extraction, Vegetable oils, Escherichia coli
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Background
Terpenoids, also known as isoprenoids, are one of the 
largest and most diverse classes of naturally occurring 
products [1]. In animals, terpenoids play crucial roles as 
membrane constituents (e.g., cholesterol) and compo-
nents of the respiratory electron transport chain (e.g., 
ubiquinone) [2], whereas in microbes and plants, they are 
found as secondary metabolites that have been used as 
pharmaceuticals (e.g., paclitaxel and artemisinin), flavors, 
and fragrances (e.g., menthol and patchoulol) [3]. Ter-
penoids, including monoterpenes, sesquiterpenes, and 
diterpenes, are synthesized by terpene synthases (TPSs) 
with universal five-carbon building units, isopentenyl 
diphosphate (IPP) and its isomer dimethyl allyldiphos-
phate (DMAPP). IPP and DMAPP are synthesized in 
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two different pathways: the mevalonate (MVA) pathway 
[4], and the 2-C-methyl-d-erythritol 4-phosphate (MEP) 
pathway [5] (Fig.  1a). In general, Gram-negative bacte-
ria, including Escherichia coli, employ the MEP pathway, 
whereas eukaryotes, archaea, humans, and Gram-pos-
itive cocci use the MVA pathway [6]. Prenyltransferases 
assemble the IPP and DMAPP units to produce the pre-
nyl diphosphates, which are terpenoid precursors, includ-
ing geranyl diphosphate (GPP, C10), farnesyl diphosphate 
(FPP, C15), and geranyl geranyl diphosphate (GGPP, C20). 
These prenyl diphosphate molecules are converted into a 
large variety of terpenoids by TPSs [7, 8].
(−)-α-Bisabolol is an unsaturated sesquiterpene alcohol 
that occurs naturally in the Brazilian candeia tree (Ere-
manthus erythropappus) and in medicinal herbs such as 
German chamomile (Matricaria recutita) [9, 10]. It has 
been shown to have pharmaceutical functions (e.g., anti-
bacterial, antiseptic, and anti-inflammatory activities), 
and skin-soothing and -moisturizing properties [11–13]. 
Owing to the low toxicity associated with (−)-α-bisabolol, 
the Food and Drug Administration (FDA) has granted it 
the Generally Regarded as Safe (GRAS) status that has 
promoted its use as an active ingredient in several com-
mercial products [14]. At present, natural (−)-α-bisabolol 
is primarily manufactured through the steam-distillation 
of candeia essential oils extracted from the Brazilian 
candeia tree, which has raised environmental and bio-
conservation issues in recent years [10]. (−)-α-Bisabolol 
can also be chemically synthesized; however, chemical 
synthesis requires an additional economically unviable 
purification step because of the formation of other dias-
tereomers ((+)-α-bisabolol and (±)-epi-α-bisabolol) and 
undesirable byproducts [15]. Therefore, a sustainable 
supply of nature-identical (−)-α-bisabolol is essential to 
specialty chemical industries. Recently, a (−)-α-bisabolol 
synthase capable of synthesizing enantio-selective 
(−)-α-bisabolol as a single terpenoid product has been 
identified in German chamomile. (−)-α-bisabolol syn-
thase was expressed in Saccharomyces cerevisiae for the 
production of (−)-α-bisabolol and had a yield of 8 mg/L 
after 4  days of cultivation [15]. This previous study has 
paved the way for the biological production of enantiose-
lective (−)-α-bisabolol in engineered microorganisms, 
but the productivity is very low for industrial production 
of (−)-α-bisabolol.
The aim of this study was to produce (−)-α-bisabolol by 
large-scale fermentation of E. coli, which has been widely 
used for various industrial applications, and to develop 
an economically viable direct (−)-α-bisabolol extraction 
process during fermentation. To achieve this, we cre-
ated (−)-α-bisabolol-producing E. coli in three steps: (1) 
We introduced the German chamomile (−)-α-bisabolol 
synthase gene (MrBBS) into E. coli convert endogenous 
FPP to (−)-α-bisabolol; (2) We engineered the exogenous 
MVA pathway to increase IPP and DMAPP pool; and (3) 
We overexpressed an ispA gene encoding an FPP syn-
thase that efficiently provides the (−)-α-bisabolol precur-
sor (FPP) from IPP and DMAPP (Fig. 1b).
Methods
Bacterial strains, media, and culture conditions
Strains used in this study are listed in Table  1. E. 
coli DH5α was used for cloning experiments and 
(−)-α-bisabolol production. BL21(DE3) and MG1655 
strains were used to compare effects of differ-
ent host strains on the production and toxicity of 
(−)-α-bisabolol. E. coli strains were grown in Luria 
Bertani (LB) medium (10  g/L tryptone, 5  g/L yeast 
extract, and 5  g/L NaCl) for cloning experiments and 
(−)-α-bisabolol production. To produce (−)-α-bisabolol 
in E. coli, we used various media at 30 °C and 200 rpm; 
terrific broth (TB) medium (12  g/L enzymatic casein 
digest, 24  g/L yeast extract, 9.4  g/L K2HPO4, and 
2.2  g/L KH2PO4), 2xYT medium (16  g/L tryptone, 
10 g/L yeast extract, and 5 g/L NaCl), and M9 minimal 
medium (6.78  g/L Na2HPO4, 3  g/L KH2PO4, 0.5  g/L 
NaCl, 1 g/L NH4Cl, 0.241 g/L MgSO4, 0.0111 g/L CaCl2, 
and 0.1  g/L thiamine). M9 minimal medium was sup-
plemented with 4  g/L of glucose. Ampicillin (100  μg/
mL), chloramphenicol (34  μg/mL), or isopropyl β-d-1-
thiogalactopyranoside (IPTG) as required.
n-Dodecane was used as an overlay to prevent the loss 
of volatiles. Furthermore, n-dodecane was used to solu-
bilize and extract (−)-α-bisabolol, which is toxic to E. 
coli cell growth in high concentrations, from the culture 
media during cultivation. MVA was prepared from meva-
lonolactone (Sigma Aldrich) as previously described [16]. 
Cell growth was monitored by measuring the optical 
density at a wavelength of 600 nm (OD600) with a spec-
trophotometer (Ultrospec 8000, GE Healthcare, Uppsala, 
Sweden). The inhibitory effect of (−)-α-bisabolol on the 
growth of E. coli strains was investigated in LB liquid 
medium supplemented with various concentrations of 
(−)-α-bisabolol. Diluted samples from cultures during 
the stationary phase were plated on LB solid medium and 
the colony-forming units (CFUs) were determined after 
overnight incubation at 30 °C.
Plasmid construction
Plasmids and polymerase chain reaction (PCR) primers 
used in this study are listed in Table  1. Common proce-
dures, including genomic DNA preparation, restriction 
digestions, transformations, and other standard molecu-
lar biological techniques were performed as previously 
described [17]. All restriction enzymes and T4 DNA ligase 
were purchased from New England Biolabs (Ipswich, 
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USA). PCR was performed following the manufacturer’s 
instructions, using a high fidelity KOD-Plus-Neo poly-
merase (Toyobo, Osaka, Japan). Plasmid preparation and 
gel extraction kits were obtained from Promega (Madison, 
USA) and oligonucleotides were synthesized by Bioneer 
(Daejeon, Korea). The MrBBS gene (GenBank acces-
sion number: KJ020282) was optimized to E. coli codons 
and synthesized by Bioneer (Additional file 1: Figure S1). 
We deposited the nucleotide sequence data of E. coli 
codon-optimized MrBBS in the GenBank database (acces-
sion number: KU680479). The synthesized MrBBS was 
amplified by PCR with Bis-IF and Bis-IR primers (Table 1) 
and the plasmid backbone was amplified with the Bis-
VF and Bis-VR primers from pTrc99A (GE Healthcare). 
The two PCR-amplicons were assembled via the Gibson 
Assembly Method [18] using Gibson Assembly Master 
Mix (New England Biolabs), to produce the pTSN-MrBBS 
plasmid. The entire polycistronic MVA pathway genes 
Fig. 1 Biosynthesis of (−)‑α‑bisabolol in engineered E. coli. a Schematic representation of (−)‑α‑bisabolol production in an engineered E. coli 
harboring endogenous 2‑C‑methyl‑d‑erythritol 4‑phosphate (MEP) pathway genes and exogenous mevalonate (MVA) pathway genes. The native 
MEP pathway consists of: DXS deoxyxylulose 5‑phosphate synthase; DXR deoxyxylulose 5‑phosphate reductoisomerase; CMS 2‑C‑methylerythritol 
4‑phosphate cytidyl transferase; CMK 4‑(cytidine 5′‑diphospho)‑2‑C‑methylerythritol kinase; MDS 2‑C‑methylerythritol 2,4‑cyclodiphosphate 
synthase; HDS (E)‑4‑hydroxy‑3‑methylbut‑2‑enyl diphosphate reductase; and HDR hydroxymethylbutenyl diphosphate reductase. The engineered 
mevalonate pathway consists of seven enzymes: MvaE, acetoacetyl‑CoA thiolase (GenBank accession number: AF290092); MvaS, 3‑hydroxy‑3‑meth‑
ylglutaryl‑ CoA synthase (GenBank accession number: AF290092); MvaA, 3‑hydroxy‑3‑methylglutaryl‑CoA reductase (GenBank accession number: 
AF290092); MvaK1, mevalonate kinase (GenBank accession number: AF290099); MvaK2, phosphomevalonate kinase (GenBank accession number: 
AF290099); MvaD, mevalonate 5‑diphosphate decarboxylase (GenBank accession number: AF290099); Idi, isopentenyl diphosphate isomerase 
(GenBank accession number: AF119715); and IspA, geranyl diphosphate synthase or farnesyl diphosphate synthase (GenBank accession number: 
AAC73524). MrBBS; E. coli codon‑optimized (−)‑α‑bisabolol synthase of German chamomile (GenBank accession number: KU680479). b Plasmid 
constructs used for (−)‑α‑bisabolol production in E. coli. pTSN‑MrBBS, pTrc99A with MrBBS gene from German chamomile; pSSN12Didi, pSTV28 
containing mvaK1, mvaD, mvaK2 of Streptococcus pneumoniae, and idi of Escherichia coli; pSNA‑MrBBS, pSTV28 containing mvaK1, mvaK2, and mvaD 
of S. pneumoniae, idi of E. coli, mvaE and mvaS of Enterococcus faecalis, and MrBBS of German chamomile; pSNA‑MrBBS‑IspA, pSNA‑MrBBS containing 
ispA of E. coli
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were inserted into pTSN-MrBBS through XbaI restric-
tion site digestion of both the pTSN-MrBBS and the pSNA 
plasmids containing all the mevalonate pathway genes 
[19], followed by ligation with T4 DNA ligase. The result-
ant plasmid was designated pSNA-MrBBS. To overexpress 
FPP synthase, the ispA gene (GenBank accession num-
ber: AAC73524) was PCR-amplified from E. coli MG1655 
genomic DNA, using IspAI-F and IspAI-R primers. To 
avoid proofreading errors introduced during PCR, the 
amplified ispA gene was first inserted into the XbaI restric-
tion site of pTSN-MrBBS (instead of pSNA-MrBBS). The 
pTSN-MrBBS-IspA and pSNA plasmids were digested 
with XbaI followed by ligation with T4 DNA ligase to cre-
ate pSNA-MrBBS-IspA. The direction of the MVA path-
way genes was verified by Sanger sequencing.
Batch and fed‑batch fermentation
To prepare the pre-culture, the engineered E. coli was 
cultured in 100 mL of TB medium at 30 °C and 180 rpm. 
The batch fermentation was performed by inoculating 
1% (v/v) of pre-culture into 400  mL  TB medium sup-
plemented with 10 g/L glycerol and overlaid with 80 mL 
n-dodecane in a 1  L fermenter. The cultures were incu-
bated at 30 °C and air-aerated with a flow rate of 1 volume 
of air per volume of medium per min (vvm), the agita-
tion speed remained fixed at 200 rpm in all experiments. 
Glycerol was used as a carbon source at a concentration 
of 10 g/L. The pH was balanced to pH 7.0 by the addition 
of 1 M HCl and 25% NH4OH solutions. n-Dodecane was 
overlaid up to 20% (v/v) of culture volume to continu-
ously extract (−)-α-bisabolol from the culture broth dur-
ing fermentation. The fed-batch fermentation began as a 
batch operation and was switched to the fed-batch mode 
at 24 h, when OD600 reached 3.0. At the beginning of fed-
batch fermentation, TB medium was supplemented with 
10 g/L glycerol, 0.1% (v/v) trace element solution (27 g/L 
FeCl3·6H2O, 2 g/L ZnCl2·4H2O, 2 g/L CoCl2·6H2O, 2 g/L 
Na2MoO4·2H2O, 1 g/L CaCl2·2H2O, 1.3 g/L CuCl2·6H2O, 
and 0.5 g/L H3BO3) and 1% (v/v) vitamin solution (Sigma 
Aldrich, Cat. No. M6895). Glycerol was then fed at a rate 
Table 1 List of strains, plasmids, and primers used in this study
Overlap region for Gibson Assembly is underlined
a Primer sequences are indicated in the 5′–3′ direction
Name Description Refs
Strains
 DH5α F−, Φ80lacZ·ΔM15·ƒ(lacZYA−argF)U169 deoR recA1 endA1 hsdR17(rk−, mk+) phoA supE44 thi‑1 gyrA96 relA1 Enzynomics
 MG1655 F−, λ−, ilvG−, rfb‑50, rph1 ATCC 700926
 BL21(DE3) BL21 F−, dcm ompT hsdS (rB‑ mB‑) gal λ(DE3) Enzynomics
Plasmids
 pSSN12Didi pSTV28 containing mvaK1, mvaD, mvaK2 of Streptococcus pneumoniae, and idi of E. coli [19]
 pPROLar.A Plac/ara‑1 expression vector, Kan
r, p15A ori Clontech
 pTrc99A Ptrc expression vector, Amp
r, lacIq, pBR322 ori GE Healthcare
 pTSN‑MrBBS pTrc99A containing MrBBS of Matricaria recutita This study
 pPR‑IspA pPROLar.A containing ispA of E. coli This study
 pTSN‑MrBBS‑IspA pTSN‑MrBBS containing ispA of E. coli This study
 pSNA pSTV28 containing mvaK1, mvaK2, and mvaD of S. pneumoniae, idi of E. coli, and mvaE and mvaS, of Enterococcus 
faecalis
[19]
 pSNA‑MrBBS pSNA containing MrBBS of M. recutita This study
 pSNA‑MrBBS‑IspA pSNA‑MrBBS containing ispA of E. coli This study
Primersa
 Bis‑IF aggttaaaccatgagcacactgagcgtcag This study
 Bis‑IR cgactctagattagactatcatcggatgta This study
 Bis‑VF gatagtctaatctagagtcgacctgcaggc This study
 Bis‑VR gtgtgctcatggtttaacctcctgtgtgaaattgttatc This study
 IspAI‑F ggtaccccatatggactttccgcagcaact This study
 IspAI‑R tgcctctagattatttattacgctggatga This study
 IspAV‑F taataaataatctagaggcatcaaataaaa This study
 IspAV‑R gaaagtccatatggggtacctttctcctct This study
 IspAop‑IF acatccgatgatagtctaatattcattaaagaggagaaag This study
 IspAop‑IR tgcatgcctgcaggtcgactctagattatttattacgctg This study
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of 0.01 L/h and 10% (v/v) canola oil (instead of 20% (v/v) 
n-dodecane) was used to overlay 30  L TB medium in a 
50 L fermenter.
(−)‑α‑Bisabolol extraction with n‑dodecane and vegetable 
oils
Extraction of (−)-α-bisabolol was performed using four 
common vegetable oils: canola, olive, corn, and soy-
bean oil. A total of 0.1 g of (−)-α-bisabolol was added to 
10 mL of sterile TB medium in a glass vial and 1 mL of 
(Agilent, Santa Clara, USA). The quantification of 
(−)-α-bisabolol was performed using GC equipped with 
a flame ionization detector (FID) with a HP-5 column 
(30 m × 0.320 mm × 0.25 µm) at a flow rate of 1 mL/min. 
The starting temperature of the oven was 60 °C for 2 min, 
increased at 5 °C/min to 200 °C, held at 200 °C for 2 min, 
increased by 50 °C/min to 300 °C, and held at 300 °C for 
5  min. Helium was used as the carrier gas with an inlet 
pressure of 5.58 psi. The (−)-α-bisabolol concentration 
produced by engineered E. coli was determined as follows:
(−)-α-bisabolol [mg/L] =
[(−)-α-bisabolol in n− dodecane phase]× [volume of n− dodecane phase]
[volume of medium phase]
individual vegetable oil was overlaid to the solution. After 
gentle stirring of the mixture, it was incubated at 25  °C 
for 1 h to separate the water-based TB medium and oil 
phase. The aqueous layer was removed and the organic 
layer was transferred to a new vial for gas chromatogra-
phy (GC) analysis of (−)-α-bisabolol. The recovery yield 
of each vegetable oil was compared with that of n-dode-
cane. To determine the recovery efficiency of n-dodecane 
from cell pellets and TB medium, E. coli DH5α cells 
transformed with the pSNA-MrBBS-IspA plasmid were 
cultivated in TB medium in the presence of 20% (v/v) 
n-dodecane at 30 °C at 180 rpm for 48 h. After centrifu-
gation of the culture at 14,000 rpm for 10 min, the pellet, 
supernatant, and organic layers of n-dodecane were frac-
tionated. To determine the recovery yield of n-dodecane, 
the organic layer was directly subjected to GC analysis 
of (−)-α-bisabolol. The isolated supernatant was mixed 
with 20% (v/v) n-dodecane, incubated for 30  min, and 
centrifuged at 14,000 rpm for 10 min. The organic layer 
was isolated and used for GC analysis of (−)-α-bisabolol. 
The cell pellet was first disrupted by sonication and the 
lysate was used for the extraction and quantification of 
(−)-α-bisabolol through the process described above.
(−)‑α‑Bisabolol identification and quantification
To analyze (−)-α-bisabolol production, the culture 
broth was centrifuged at 13,000  rpm for 10  min to 
separate the overlaid n-dodecane phase. The recov-
ered n-dodecane-phase was subsequently analyzed 
for (−)-α-bisabolol by GC and GC-mass spectrom-
etry (GC–MS). The identification of (−)-α-bisabolol was 
conducted by GC–MS (5977A MSD) with a HP-5MS 
column (30  m  ×  0.250  mm  ×  0.25  µm, Agilent, Santa 
Clara, USA). The column flow was maintained at 1 mL/
min. The oven temperature was initially held at 60  °C 
for 2  min, increased by 5  °C/min to 300  °C, and held at 
300  °C for 10  min. (−)-α-Bisabolol (Cat. No. 23089-
26-1, Sigma Aldrich) was used as the standard, and was 
confirmed through the GC-MS software, Mass Hunter 
Analysis of glycerol consumption and byproduct formation
The culture broth was centrifuged and the supernatant 
was used to quantify glycerol consumption and byprod-
uct formation. Glycerol, acetate, and mevalonate con-
centrations were determined by high performance liquid 
chromatography (HPLC, Shimadzu, Kyoto, Japan) with a 
refractive index detector at 454 nm using Aminex HPX-
87H column (1300  mm  ×  7.8  mm, Bio-Rad, Hercules, 
USA). Sulfuric acid (0.4  mM) was used as the mobile 
phase at a flow rate of 0.3 mL/min at 50 °C.
Results and discussion
Suitability of E. coli DH5α as a host for (−)‑α‑bisabolol 
production
(−)-α-Bisabolol is a naturally occurring sesquiterpene 
alcohol that exhibits antibacterial activity [13]. This 
property would be a hurdle for the use of E. coli as a ter-
penoid production host [20]. Therefore, we examined 
the suitability of three different E. coli strains [DH5α, 
MG1655, and BL21(DE3)] for (−)-α-bisabolol produc-
tion by conducting growth assays in LB in the presence 
of various concentrations of (−)-α-bisabolol (Fig.  2). 
After 3  h of cultivation (mid-log phase), the growth 
of BL21(DE3) significantly decreased by 1 and 5  g/L 
(−)-α-bisabolol (Fig.  2a). The growth of MG1655 was 
not affected by (−)-α-bisabolol at concentrations of 1 or 
5  g/L (Fig.  2a). The growth of DH5α slightly decreased 
at (−)-α-bisabolol concentration of 5  g/L, but growth 
was not affected by 1 g/L (−)-α-bisabolol (Fig. 2a). This 
result was corroborated with CFU measurements for 
each culture. As expected, DH5α showed the best toler-
ance to (−)-α-bisabolol whereas BL21(DE3) formed no 
colonies on the solid LB medium (Fig. 2b). These results 
are consistent with a previous study showing that of five 
different B- and K-type E. coli strains (MG1655, DH5α, 
S17-1, XL1-Blue, and BL21), DH5α is the best producer 
of the β-carotene (C40) terpenoid [21]. In addition, E. 
coli DH5α has been used for production of retinol [22], 
farnesol [23], and protoilludene [23]. We concluded that 
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E. coli DH5α is suitable as a host for (−)-α-bisabolol pro-
duction and it was used for all subsequent experiments.
(−)‑α‑Bisabolol production in E. coli DH5α expressing the 
MrBBS gene
To implement the de novo production of (−)-α-bisabolol 
in E. coli DH5α, the gene of MrBBS, encoding the 
(−)-α-bisabolol synthase, was codon-optimized for 
E. coli and introduced via the pTSN-MrBBS plasmid 
(Fig. 1b). The resulting transformant cells were cultured 
in LB medium overlaid with 20% (v/v) n-dodecane for 
48  h. Two-phase cultures have been successfully used 
to extract toxic, water-immiscible or volatile prod-
ucts [24–26] and n-dodecane was successfully used for 
extraction of (−)-α-bisabolol from the culture broth 
of S. cerevisiae [15]. As expected, in the present study, 
(−)-α-bisabolol was extracted into the n-dodecane phase 
in the two-phase E. coli culture. As the (−)-α-bisabolol 
was recovered in n-dodecane without significant residual 
amounts left in the cells (Additional file  1: Figure S2), 
(−)-α-bisabolol purification in a later step will be facili-
tated. The n-dodecane phase was used for GC analysis 
to measure (−)-α-bisabolol concentrations. There was 
a peak at 25.6 min in the n-dodecane phase sample of 
E. coli DH5α with pTSN-MrBBS, corresponding to the 
standard (−)-α-bisabolol compound dissolved in n-dode-
cane (Fig.  3a). Mass spectrometry confirmed that the 
peak at 25.6 min was (−)-α-bisabolol (Fig.  3b, c) and a 
maximum concentration of 3  mg/L (−)-α-bisabolol was 
produced by the endogenous MEP pathway and exog-
enous MrBBS enzyme in E. coli DH5α. The peak was not 
observed in two-phase cultures of DH5α cells contain-
ing an empty plasmid as a control experiment (Fig.  3a). 
The (−)-α-bisabolol synthase gene, MrBBS, used in 
this study was recently isolated from German chamo-
mile and, unlike other TSPs, exclusively synthesizes 
(−)-α-bisabolol as a single terpene product [15]. Several 
TPSs producing α-bisabolol as a single major product 
have been previously cloned and biochemically charac-
terized. However, these enzymes usually produce unde-
sirable isomers with different structures or α-bisabolol of 
unknown stereochemistry [27–29]. The MrBBS enzyme 
has shown unique catalytic features including the forma-
tion of a single enantiopure (−)-α-bisabolol indicating 
the possibility of a biotechnological application to natu-
ral (−)-α-bisabolol production in S. cerevisiae [15]. Here, 
we have expressed the codon-optimized synthetic MrBBS 
in E. coli and successfully produced (−)-α-bisabolol 
(titer: 3 mg/L). A similar result has been observed when 
attempting to express other plant terpene synthases in E. 
coli [30, 31].
(−)‑α‑Bisabolol production in E. coli DH5α expressing 
MrBBS and MVA pathway genes
Terpenoid production in microbes is mainly limited 
by the flux from intermediates of central metabo-
lism (acetyl-CoA for MVA pathway or pyruvate and 
glyceraldehyde-3-phosphate for MEP pathway) to 
the substrates of TPSs (GPP, FPP, or GGPP) [32]. The 
introduction and engineering of the biosynthetic MVA 
pathway in E. coli have improved the production of 
terpenoids such as amorphadiene [32], carotenoids 
[19, 21], coenzyme Q10 [33], and farnesol [30] by effi-
ciently supplying IPP and DMAPP. Based on these 
studies, we exploited the biosynthetic MVA pathway 
for the biosynthesis of (−)-α-bisabolol in E. coli. To 
increase carbon flux towards TPS substrates, a plas-
mid (pSSN12Didi) containing the lower MVA pathway 
Fig. 2 Growth inhibition of E. coli strains by exogenous (−)‑α‑bisabolol. a Time course of growth profile. b CFU measurement. Cells were grown in 
LB liquid medium and different amounts of (−)‑α‑bisabolol were added at the beginning of cultivation. Samples were taken for measurement of 
optical density at 600 nm (OD600). Samples for CFU measurement were taken at early stationary phase (indicated by an arrow). Mean values of two 
independent experiments are given for the CFU measurement
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Fig. 3 GC and GC–MS analysis of n‑dodecane extracts from E. coli expressing the MrBBS gene. a Total ion chromatograms of an authentic 
(−)‑α‑bisabolol standard (100 mg/L) and the n-dodecane extracts from the E. coli expressing MrBBS (pTSN‑MrBBS) or containing an empty vector 
(pTrc99A). b Mass spectra of (−)‑α‑bisabolol standard. c Mass spectra of (−)‑α‑bisabolol produced in E. coli cells harboring the plasmid pTSN‑MrBBS. 
Each cell was cultivated in LB medium overlaid with 20% (v/v) n‑dodecane at 30 °C for 48 h
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genes (Fig. 1b), leading from MVA to IPP and DMAPP 
[30], was introduced into E. coli DH5α expressing the 
MrBBS. MVA is an exogenous substrate for E. coli, so 
supplemented MVA can only be converted to IPP and 
DMAPP by the engineered MVA lower pathway in E. 
coli. Different concentrations of MVA, ranging from 0 
to 10 mM, were examined to determine whether MVA 
availability limits (−)-α-bisabolol production in LB 
medium. (−)-α-bisabolol production increased as the 
concentration of the supplied MVA increased (Fig. 4a) 
and cell growth was not significantly inhibited (Fig. 4b). 
With the addition of 10  mM MVA, (−)-α-bisabolol 
production was 10.5  mg/L, approximately 3.5-fold 
higher than that obtained without the addition of MVA 
(3  mg/L, Fig.  4a). Expression of the lower MVA path-
way genes in E. coli improved (−)-α-bisabolol pro-
duction with the addition of MVA. However, MVA 
is not an economically viable substrate. To achieve 
(−)-α-bisabolol production from cost-effective renew-
able resources such as glycerol, a major byproduct 
of the biodiesel industry, we constructed a plasmid 
pSNA-MrBBS (Fig.  1b). pSNA-MrBBS harbors the 
complete biosynthetic MVA pathway genes, including 
the MrBBS gene, and enables production of IPP and 
DMAPP in the absence of MVA. A total of 12.8  mg/L 
of (−)-α-bisabolol was produced from glycerol in E. coli 
DH5α with pSNA-MrBBS grown in LB (Fig.  5a). This 
is a slightly higher concentration than that produced in 
DH5α containing only MrBBS and lower MVA pathway 
genes with the addition of 10  mM MVA (10.5  mg/L). 
Overall, the expression of biosynthetic MVA pathway 
genes significantly improved (−)-α-bisabolol produc-
tion in E. coli.
Optimization of (−)‑α‑bisabolol production in E. coli DH5α 
expressing MrBBS and entire MVA pathway genes
IPP and DMAPP, precursors of FPP, are essential metab-
olites in E. coli that are used for tRNA prenylation, syn-
thesis of quinone and dolichol for respiration, and cell 
wall biosynthesis [31]. Thus, the metabolic balance of IPP 
and DMAPP between endogenous essential metabolism 
and exogenous (−)-α-bisabolol production plays a crucial 
role in improving production of (−)-α-bisabolol and alle-
viation of growth inhibition. To determine the optimal 
IPP and DMAPP pool balancing conditions in the engi-
neered E. coli harboring the entire MVA pathway and 
MrBBS genes (pSNA-MrBBS), we examined if cultivation 
media and glycerol availability limit (−)-α-bisabolol pro-
duction. To do this we tested different media and concen-
trations of glycerol ranging from 0 to 3.5% (w/v) (Fig. 5a). 
E. coli DH5α containing the pSNA-MrBBS produced the 
highest concentration of (−)-α-bisabolol (24.2  mg/L) in 
TB medium without the addition of an additional car-
bon source (Fig.  5a). (−)-α-Bisabolol production was 
dependent on the amount of provided glycerol in the TB 
medium. With 1% (w/v) glycerol, (−)-α-bisabolol con-
centration was 38.3 mg/L, approximately 1.4-fold higher 
than the concentration of (−)-α-bisabolol obtained with-
out the inclusion of glycerol. However, 3.5% (w/v) of glyc-
erol concentration did not show further improvement of 
(−)-α-bisabolol production (Fig. 5a). Because cell growth 
of E. coli DH5α varied in different culture media, the 
Fig. 4 The effect of mevalonate concentration on (−)‑α‑bisabolol production (a) and final OD600 (b) from engineered E. coli harboring pTSN‑MrBBS 
and pSSN12Didi. Cells were grown at 30 °C in LB medium supplemented with different concentrations of mevalonate and 20% (v/v) n‑dodecane for 
48 h. Data represent averages from three replicate cultures; error bars show SD
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differences in (−)-α-bisabolol production are partly due 
to differences in growth (Figure S3A).
Plasmid pSNA-MrBBS contained IPTG-inducible lac 
and trc promoters for expression of the complete MVA 
pathway genes and MrBBS gene, respectively (Fig.  1b). 
To ascertain the optimal inducer concentration for 
(−)-α-bisabolol production in E. coli DH5α with pSNA-
MrBBS, induction was conducted with varying concen-
trations of IPTG ranging from 0 to 0.1 mM. Interestingly, 
leaky expression of the MrBBS and MVA pathway genes 
in the absence of IPTG showed the highest produc-
tion of (−)-α-bisabolol (38.9  mg/L). At all other IPTG 
concentrations (−)-α-bisabolol production decreased 
as the IPTG concentration increased (Fig.  5b) whereas 
the growth of E. coli DH5α cells is similar regardless of 
IPTG concentration (Additional file 1: Figure S3B). This 
result is compatible with a previous report [31] that 
showed lycopene production in E. coli expressing lower 
MVA pathway genes regulated by the trc promoter 
decreased under all IPTG-induced conditions. In addi-
tion, constitutive promoters controlling the expression 
of MVA pathway genes showed much lower produc-
tion of amorphadiene than that from IPTG-inducible 
lacUV5 and trc promoters [34]. High expression of the 
Fig. 5 Optimal conditions for (−)‑α‑bisabolol production in E. coli expressing MrBBS and all MVA pathway genes. E. coli cells harboring pSNA‑MrBBS 
were grown for 48 h at 30 °C in the presence of 20% (v/v) n‑dodecane with the following variations; a Medium (M9 supplemented with 4 g/L glu‑
cose, LB, 2xYT, TB) and glycerol concentration; b IPTG concentration. When OD600 reached 0.5, different concentrations of IPTG were added to the E. 
coli cells grown on TB medium supplemented with 10 g/L glycerol; c pH. Different initial pHs were tested to find an optimal pH for (−)‑α‑bisabolol 
production. E. coli cells were cultivated in TB medium containing 10 g/L glycerol in the absence of IPTG; d E. coli strains. E. coli cells were grown on TB 
medium, pH 7.0 with 10 g/L glycerol and 20% (v/v) n‑dodecane in the absence of IPTG. Data represent averages from three replicate cultures and 
error bars show SD
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MVA pathway and MrBBS genes under IPTG induced 
conditions could cause a deficiency of FPP for essential 
cellular metabolism. Furthermore, the accumulation of 
toxic intermediates of the MVA pathway, including IPP 
and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) 
[32, 35], could cause growth inhibition along with a 
decrease of (−)-α-bisabolol production. In addition, we 
investigated the effects of initial pH of the cultivation of 
E. coli DH5α with pSNA-MrBBS on the production of 
(−)-α-bisabolol. The optimal pH for (−)-α-bisabolol pro-
duction was pH 7 (38.2 mg/L, Fig. 5c). To determine the 
ideal E. coli strains for (−)-α-bisabolol production under 
the optimized culture conditions, we individually intro-
duced the plasmid pSNA-MrBBS into three different E. 
coli strains (DH5α, MG1655, or BL21(DE3)) and meas-
ured the (−)-α-bisabolol concentration produced from 
each. E. coli DH5α cells produced the highest amount 
of (−)-α-bisabolol, and BL21(DE3) showed an approxi-
mate 13-fold decrease in (−)-α-bisabolol production 
compared to DH5α (38.4 mg/L, Fig. 5d). We also meas-
ured cell growth during examination of pH effects on 
(−)-α-bisabolol production in E. coli DH5α expressing 
MrBBS and entire MVA pathway genes. Although cell 
growth slightly decreased at a pH 5 or 6, it was similar at 
all other pHs (Additional file 1: Figure S3C).
Effect of the overexpression of FPP synthase 
on (−)‑α‑bisabolol production
(−)-α-Bisabolol is produced from depyrophosphoryla-
tion of the prenyl diphosphate precursor FPP. Therefore, 
synthesis of FPP from IPP and DMAPP by FPP synthase, 
encoded by the ispA gene, plays a key role in the improved 
production of (−)-α-bisabolol. Furthermore, high con-
centrations of prenyl diphosphates, such as FPP, are toxic 
to E. coli cell growth [36]. FPPs needs to be efficiently 
converted into downstream products by TPSs to reduce 
its toxicity. To increase the synthesis of the cellular terpe-
noid biosynthesis intermediate FPP, and (−)-α-bisabolol 
production, overexpression of an FPP synthase, encoded 
by the ispA gene, was performed. The ispA gene of E. coli 
was inserted downstream of the MrBBS gene in the plas-
mid pSNA-MrBBS, resulting in the pSNA-MrBBS-IspA 
plasmid (Fig.  1b). This plasmid was transformed into E. 
coli DH5α and cultivated in TB medium containing 1% 
(w/v) glycerol at 30 °C for 48 h using a two-phase culture 
without the addition of IPTG. Overexpression of the ispA 
gene improved (−)-α-bisabolol production compared 
with pSNA-MrBBS alone. After 48 h, a concentration of 
79.7 mg/L of (−)-α-bisabolol was obtained in a culture of 
DH5α with pSNA-MrBBS-IspA. This was twofold higher 
than the 39.7 mg/L of (−)-α-bisabolol produced by DH5α 
with pSNA-MrBBS alone (Fig.  6a), without significant 
difference in cell growth (Additional file 1: Figure S3D). 
This suggested that sufficient supply of FPP is important 
to improve (−)-α-bisabolol production in E. coli. While 
overexpressing the ispA gene, 0.05  mM IPTG at OD600 
~0.5 was added to induce expression of the MVA path-
way and MrBBS genes. Similar to the results without ispA 
overexpression, (−)-α-bisabolol production decreased 
from 87.8  mg/L (no IPTG) to 40  mg/L (−)-α-bisabolol 
(0.05  mM IPTG, Fig.  6b) with no significant difference 
in cell growth (Additional file  1: Figure S3D). To moni-
tor the time-course of (−)-α-bisabolol production, batch 
fermentation of E. coli DH5α harboring the pSNA-
MrBBS-IspA plasmid, using a 1  L fermenter, was con-
ducted at 30 °C in the absence of IPTG for 93 h (Fig. 6c). 
(−)-α-bisabolol production of 214  mg/L was achieved 
and cell growth reached an OD600 value of 11.5 after 93 h. 
MVA and acetate were the main byproducts, although 
the acetate was consumed after glycerol depletion at 
48  h. The solubility of heterologous enzymes increases 
at lower growth temperatures because the transcription 
rate is slower, leading to better protein folding in E. coli 
[37, 38]. In addition, improved solubility of metabolic 
pathway enzymes at low temperature enhances the pro-
duction yield [39]. Therefore, we performed the batch 
fermentation at 25 °C under the same conditions. Indeed, 
(−)-α-bisabolol production was 342 mg/L after fermen-
tation for 93  h, approximately 1.6-fold higher than that 
obtained at 30  °C, and cell growth decreased by 25% 
(OD600 8.7, Fig. 6d).
Extraction and fed‑batch fermentation of (−)‑α‑bisabolol
n-Dodecane has been mostly used for the extraction of 
terpenoids produced in microorganisms due to its rela-
tively low volatility, enabling continuous extraction over 
multiple days [40]. The (−)-α-bisabolol produced in 
flask culture and batch fermentation could be efficiently 
extracted from the broth to the overlaid n-dodecane 
phase. The in  situ recovery of (−)-α-bisabolol from the 
n-dodecane phase during culture can reduce production 
costs by simplifying both the harvest and purification 
processes. However, n-dodecane is not an economically 
viable extracting solvent. We assessed various natural and 
inexpensive vegetable oils for selective (−)-α-bisabolol 
extraction from fermentation broth. As shown in Table 2, 
all tested vegetable oils showed extraction yields rang-
ing from 96.6 to 98.8%, which are comparable to that of 
n-dodecane (99.5%). Among them, canola oil (98.8%) was 
the best extracting oil and was used for the extraction of 
(−)-α-bisabolol during fed-batch fermentation. A greener 
extraction of (−)-α-bisabolol plays a key role in the appli-
cation of (−)-α-bisabolol produced from fermentation 
broth to pharmaceutical and cosmetic products. We suc-
cessfully used vegetable oils as natural, cost-effective, 
and biodegradable extractors for in  situ extraction of 
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(−)-α-bisabolol during fermentation. Moreover, due to 
the difference in polarity between the fermentation broth 
(water based) and vegetable oils, there is a phase separa-
tion, resulting in isolation of oil from the broth contain-
ing cell debris. This in  situ (−)-α-bisabolol separation 
from the fermentation broth can also alleviate produc-
tion inhibition and improve (−)-α-bisabolol production, 
which will be of interest in industrial processes. To exam-
ine the production performance of (−)-α-bisabolol under 
conditions more relevant to industrial processes, we con-
ducted (−)-α-bisabolol fermentation in a 50 L fermenter 
with a fed-batch mode. E. coli DH5α, containing pSNA-
MrBBS-IspA, was grown at 25  °C with 10% (v/v) canola 
oil as an extracting solution. The final (−)-α-bisabolol 
titer reached 3.3 g/L after 90 h of fermentation, which was 
almost 8.4-fold higher than that obtained from the batch 
fermentation at 25  °C (Fig.  7). At the beginning of fer-
mentation, MVA was accumulated until depletion of the 
initial 10 g/L glycerol. After complete depletion of initial 
glycerol, MVA was consumed and (−)-α-bisabolol accu-
mulated continuously up to 9.1 g/L at the end of fermen-
tation (Fig.  7). The specific (−)-α-bisabolol production 
Fig. 6 IspA overexpression and batch fermentation of engineered E. coli. a Improvement of (−)‑α‑bisabolol production in E. coli DH5α trans‑
formed with pSNA‑MrBBS‑IspA compared with DH5α harboring the pSNA‑MrBBS plasmid. Cells were cultivated in TB medium containing 10 g/L 
glycerol at 30 °C for 48 h using two‑phase culture without the addition of IPTG. Data represent averages from three replicate cultures; error bars 
show SD, b effects of IPTG addition on (−)‑α‑bisabolol production in E. coli DH5α harboring pSNA‑MrBBS‑IspA. Culture conditions were the same 
as in Fig. 6a, except for the addition of IPTG. IPTG was added to each culture to a final concentration of 0.05 mM when the OD600 reached 0.5. Data 
represent averages from three replicate cultures; error bars show SD, c time profile of batch fermentation of E. coli DH5α with pSNA‑MrBBS‑IspA in 
TB medium containing 10 g/L of glycerol as carbon source at 30 °C, n‑dodecane was overlaid up to 20% (v/v) of culture volume to continuously 
extract (−)‑α‑bisabolol from the culture broth during fermentation. d Time profile of batch fermentation of E. coli DH5α with pSNA‑MrBBS‑IspA in 
TB medium containing 10 g/L of glycerol as carbon source at 25 °C. n‑Dodecane was overlaid up to 20% (v/v) of culture volume to continuously 
extract (−)‑α‑bisabolol from the culture broth during fermentation
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and productivity reached 0.18 g/g dry cell weight (DCW) 
and 1.24 g/L/day, respectively. A previous study reported 
the production of 8 mg/L of (−)-α-bisabolol from S. cer-
evisiae by overexpressing the MrBBS gene for 4 days [15]. 
In this study, two-phase fed-batch fermentation of the 
DH5α strain expressing the MrBBS, entire MVA path-
way, and ispA genes yielded 9.1  g/L of (−)-α-bisabolol 
after 150  h, a 1137-fold increase from that reported in 
the previous study. Since the (−)-α-bisabolol intermedi-
ate, mevalonate, accumulated after glycerol depletion, 
(−)-α-bisabolol production would increase if we increase 
expression of the genes of the lower MVA pathway. 
Such adjustments will be the content of further work to 
improve (−)-α-bisabolol production.
Conclusions
In this study, we have engineered E. coli for de novo 
production of (−)-α-bisabolol for the first time. Intro-
duction of the MVA pathway, (−)-α-bisabolol synthase 
from German chamomile, and FPP synthase turned 
E. coli into a microbial cell factory for the de novo pro-
duction of (−)-α-bisabolol from the renewable car-
bon source, glycerol. Using Canola oil as an extraction 
solvent, the engineered E. coli strain produced 9.1 g/L of 
(−)-α-bisabolol from glycerol in a fed-batch fermenta-
tion system, and the specific (−)-α-bisabolol production 
and productivity reached 0.18  g/g DCW and 1.24  g/L/
day, respectively. To the best of our knowledge, this is 
the first report demonstrating that a large amount of 
(−)-α-bisabolol could be produced by metabolically engi-
neered E. coli. Although more work is needed to optimize 
the fermentation process, the strains developed in this 
study will serve as promising platform hosts for devel-
opment of microbial production of (−)-α-bisabolol on a 
large scale. Moreover, a more environmentally friendly 
means to extract (−)-α-bisabolol, using vegetable oils, 
will reduce the production cost in an industrial process.
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Fig. 7 Fed‑batch fermentation of E. coli DH5α in TB medium sup‑
plemented with 10 g/L of glycerol as initial carbon source. After 
complete depletion of glycerol, glycerol was fed at 3 g/L/h. Concen‑
trations of acetate, mevalonate, and glycerol were determined by 
HPLC and (−)‑α‑bisabolol content was measured using GC. Canola oil 
10% (v/v) instead of n‑dodecane 20% (v/v) was used to overlay 30 L 
TB medium in a 50 L fermenter
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